91 related articles for article (PubMed ID: 16153399)
1. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Jerling M; Abdallah H
Clin Pharmacol Ther; 2005 Sep; 78(3):288-97. PubMed ID: 16153399
[TBL] [Abstract][Full Text] [Related]
2. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets.
Abdallah H; Jerling M
J Clin Pharmacol; 2005 Jul; 45(7):802-9. PubMed ID: 15951470
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Smith W; Swan S; Marbury T; Henney H
J Clin Pharmacol; 2010 Feb; 50(2):151-9. PubMed ID: 19966074
[TBL] [Abstract][Full Text] [Related]
5. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.
Jerling M; Huan BL; Leung K; Chu N; Abdallah H; Hussein Z
J Clin Pharmacol; 2005 Apr; 45(4):422-33. PubMed ID: 15778423
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment.
Swan SK; Smith WB; Marbury TC; Schumacher M; Dougherty C; Mico BA; Villano SA
J Clin Pharmacol; 2007 Feb; 47(2):209-17. PubMed ID: 17244772
[TBL] [Abstract][Full Text] [Related]
7. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Koren MJ; Crager MR; Sweeney M
J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
[TBL] [Abstract][Full Text] [Related]
9. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.
Small DS; Wrishko RE; Ernest CS; Ni L; Winters KJ; Farid NA; Li YG; Brandt JT; Salazar DE; Borel AG; Kles KA; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):585-94. PubMed ID: 19744014
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
[TBL] [Abstract][Full Text] [Related]
13. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
14. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
15. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry.
Penman AD; Eadie J; Herron WJ; Reilly MA; Rush WR; Liu Y
Rapid Commun Mass Spectrom; 1995; 9(14):1418-30. PubMed ID: 8534891
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of nelfinavir in subjects with hepatic impairment.
Damle B; Hewlett D; Hsyu PH; Becker M; Petersen A
J Clin Pharmacol; 2006 Nov; 46(11):1241-9. PubMed ID: 17050789
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of ranolazine.
Jerling M
Clin Pharmacokinet; 2006; 45(5):469-91. PubMed ID: 16640453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
